title: Chronic ivacaftor treatment: getting F508del-CFTR into more trouble?
authors.affiliation: Department of Translational Pulmonology, Translational Lung Research Center Heidelberg (TLRC), University of Heidelberg, Member of the German Center for Lung Research (DZL), Im Neuenheimer Feld 350, 69120, Heidelberg, Germany; Division of Pediatric Pulmonology & Cystic Fibrosis Center, University of Heidelberg, Member of the German Center for Lung Research (DZL), Heidelberg, Germany. Electronic address: Marcus.Mall@med.uni-heidelberg.de.
authors.forename: Marcus A
authors.initials: MA
authors.lastname: Mall
authors.affiliation: School of Physiology and Pharmacology, University of Bristol, Medical Sciences Building, University Walk, Bristol BS8 1TD, Bristol, UK. Electronic address: D.N.Sheppard@bristol.ac.uk.
authors.forename: David N
authors.initials: DN
authors.lastname: Sheppard
mesh_terms: D000627:Aminophenols / Q000494:pharmacology*; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000235:genetics*; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000187:drug effects*; D006801:Humans; D015363:Quinolones / Q000494:pharmacology*
chemical_list: D000627:Aminophenols; D015363:Quinolones; C093349:cystic fibrosis transmembrane conductance regulator delta F508; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; C545203:ivacaftor